0% found this document useful (0 votes)
31 views33 pages

Viral Pathogens - Part 1

The document discusses HIV, its structure, replication, and disease progression, along with prevention and treatment methods. It highlights the global prevalence of HIV, particularly in Sri Lanka, and details the mechanisms of infection and the immune response. The document also covers diagnosis criteria for AIDS and ongoing research into vaccines and treatment strategies.

Uploaded by

e23ashinka
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
31 views33 pages

Viral Pathogens - Part 1

The document discusses HIV, its structure, replication, and disease progression, along with prevention and treatment methods. It highlights the global prevalence of HIV, particularly in Sri Lanka, and details the mechanisms of infection and the immune response. The document also covers diagnosis criteria for AIDS and ongoing research into vaccines and treatment strategies.

Uploaded by

e23ashinka
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Viral Pathogens

Part one: HIV


Learning outcomes
After this lecture, you should be able to:
• Describe the structure of HIV.
• Describe the replication of the HIV virus
• Explain the disease progression following
HIV infection.
• Describe the mechanisms for prevention
of infection.
• Discuss treatment methods for HIV
infected individuals.
HIV Infections and AIDS
• HIV
– Human immunodeficiency virus
• AIDS
– Acquired immunodeficiency syndrome

• First noted in late 1970’s, early 1980’s


• Two types of virus HIV-1 and 2
• HIV-2 prevalent in West Africa (less severe)
• HIV viruses have evolved from simian viruses.
• 1959 first documented case of AIDS although initial
infection thought to have passed to human much earlier
but due to rural location went unnoticed
HIV in Sri Lanka

• Sri Lanka considered to be a low HIV


prevalence country

People Living with HIV/AIDS (January 2014)


Adults 3000
(>15 Years) (range 2000-5000)
Children
75
(<15 Years)
New Cases in 2012 280
Adult Prevalence
<0.1%
(>15 Years)
http://www.aidscontrol.gov.lk/web/index.php/en/statistics/hiv
Surveillance in Sri Lanka
• A well organised, surveillance & control
programme

http://www.aidscontrol.gov.lk/web/index.php/en
But why worry about HIV?
http://www.ipsnews.net/2014/02/hiv-dangerous-threshhold-sri-lanka/
Global prevalence
Global situation and trends

• Since the beginning of the HIV epidemic,


almost 75 million people have been
infected with the HIV virus.
• Approx 36 million people have died of HIV.
• Globally, 35.3 million [32.2–38.8 million]
people were living with HIV at the end of
2012.
HIV
• Retrovirus, genus Lentivirus
• Encodes reverse transcriptase which makes a
dsDNA from the ssRNA genome
• Enveloped virus
• Viral genes can permanently integrate into host
DNA
• HIV positive
– Have the virus within the body
• AIDS
– Have the virus and an immunosuppressive disease
• HIV can only infect host cells that have the
required CD4 marker plus a co-receptor.
Reverse transcriptase
• RNA dependant DNA polymerase, i.e. makes a
DNA copy of an RNA molecule
• Discovery of retroviruses and associated
enzymes have allowed great advances in
molecular biology. Reverse transcriptases now
produced and used routinely in the lab
• First retrovirus to be isolated was HTLV-1 from a
patient with Human T-cell leukaemia
• Reverse transcriptase of HIV very error prone,
leads to genetic instability and generation of new
strains of virus over the course of infection.
Evolution of HIV viruses
HIV virus genes

• env -encodes gp160 which is cleaved into gp120 and


gp41
– Cleavage is essential for infectivity
• gag -group specific antigen (core/capsid protein)
• pol -encodes RT polymerase, integrase, protease
• rev - protects mRNA from nucleus to cytoplasm
• nef -alteration of cell signals, progression to AIDS,
reduces the number of cell surface CD4 molecules
• vif -promotes virus assembly
• vpu -facilitates release of virus
• vpr -transport of DNA to nucleus for integration
• tat - transactivator or regulatory gene; recruits cellular co-
factors for DNA transcription
Co-receptors for HIV infection
•Two chemokine receptors – CCR5 and CXCR4 have been identified as co-
receptors for entry of HIV.

•Macrophage tropic (M-tropic) strains of HIV replicate in macrophages and CD4 T


cells
•use the chemokine receptor CCR5 (deficient individuals more resistant to
infection)

•T-Tropic isolates replicate in CD4 T cells and macrophages


• use the chemokine receptor CXCR4
• some viruses use both CXCR4 or CCR5

•Mutation in gp120 results in the shift of M to T occurs late, correlates with


progression

•Genetic mutations in the genes coding for co-receptors have been identified.
Such mutations result in increased protection against, or a delay in, HIV infection.

•New therapies may be developed based on the chemokine receptor network .


Epidemiology of HIV Infections

• Transmission occurs by direct and specific


routes:
• Through sexual intercourse
– Virus present in semen and vaginal secretions
• Transfer of blood or blood products
– Blood transfusions, intravenous drug users
• Babies can be infected before or during
birth, and from breast feeding.
• HIV does not survive long outside of the
body so not transmitted by touch, insect
bites, toilets etc
Infection
• HIV enters through mucous membrane
infects MALT (mucosal associated
lymphoid tissue)
• Virus taken up and amplified by
macrophages, can act as a reservoir and
also transport virus
• Other cells of the macrophage lineage
also infected
• Infects CD4 cells, results in increased
viral load
• Lytic infection of CD4 cells results in
destruction of cells
Primary effects of HIV infection:
– extreme leukopenia – lymphocytes in
particular
– formation of giant T cells and other syncytia
allowing the virus to spread directly from cell
to cell
– Infected macrophages release the virus in
central nervous system, with toxic effect,
inflammation.

Secondary effects of HIV:


– Destruction on CD4 lymphocytes allows for
opportunistic infections and malignancies.
Viral production latency and
reactivation
Signs and Symptoms of HIV
Infections and AIDS
• Symptoms of HIV are directly related to viral blood level
and level of T cells.
• The primary infection with HIV may go unnoticed, or is
typified by an acute flu-like illness
• A specific immune response follows with CD8 T cells vital
in controlling the virus.
• This control largely restores CD4 T cell levels but does
not eradicate HIV.
• Antibodies are detectable 8-16 weeks after infection.
• Asymptomatic phase 2-15 years (avg. 10)
• HIV gradually destroys the immune system.
• When T4 cell levels fall below 200/mL AIDS symptoms
appear including fever, swollen lymph nodes, diarrhea,
weight loss, neurological symptoms, opportunistic
infections and cancers.
Progression of infection
Diagnosis of HIV Infection

• Antibody tests
– ELISA, latex agglutination and rapid antibody tests
– rapid results but may result in false positives
– Sometimes antibodies can take some time to appear so not
always immediate
– Follow up with Western blot analysis to rule out false positives
persons who may have been exposed should be tested a second
time 3-6 months later.
• Molecular based tests
– Checking for viral genomic material (RT PCR)
– Can be used to gain an indication of viral load
– May help diagnose early infection before antibody production
Progression to AIDS
Diagnosis of AIDS is made when a person
meets the criteria:
1. Positive for the virus, and
2. They fulfill one of the additional criteria:
• They have a CD4 count of fewer than 200
cells/µl of blood.
• Their CD4 cells account for fewer than14% of all
lymphocytes.
• They experience one or more of a CDC-provided
list of AIDS-defining illnesses.
Insert Table 25.A page 776
AIDS-defining illnesses
Preventing and Treating HIV
• No widely available vaccine but this is an area of
active research
– monogamous sexual relationships
– condoms
– universal precautions for blood to prevent
transmission
– education about methods of transmission
• No cure; therapies slow down the progress of the
disease or diminish the symptoms
– inhibit viral enzymes: reverse transcriptase, protease,
integrase
– inhibit fusion
– inhibit viral translation
– highly active anti-retroviral therapy
The search for
a vaccine
Treatment strategies
Long Term Nonprogressors

• HIV-infected people who


– maintain CD+ T cell counts of at least 600 cells/ml of
blood
– have <5,000 copies of HIV RNA/ml of blood
– have remained this way for > 10 years after
documented infection
• Explanations of phenomena
– effective immune response to relatively conserved
proteins
– initial infection was with attenuated strain
– predisposing genetic differences
Directed learning
• What are the main issues around HIV vaccine
development? Do some additional reading and
make some additional notes on this subject.

• Identify some current research which is


attempting to identify additional means of
curing/preventing HIV infection other than the
vaccine strategy and make some notes on this.
What are the 3 main points to
take from this lecture?
1.

2.

3.
Suggested reading material
http://www.sciencedirect.com/science/article/pii/S01406736
11608775

http://onlinelibrary.wiley.com/doi/10.1002/9780470015902.
a0021550.pub2/full

http://onlinelibrary.wiley.com/doi/10.1002/9780470015902.
a0000410.pub2/full

http://onlinelibrary.wiley.com/doi/10.1038/npg.els.0003998/
full

You might also like